January 2010
Pharmaceutical Representative;Jan2010, Vol. 40 Issue 1, p7
The article offers news briefs in the pharmaceutical industry in the U.S. Pfizer Inc. strengthens its research and development facilities after its acquisition of Wyeth. Bristol-Myers Squibb Co. agrees with Tranzyme Pharma for its drug development. Novo Nordisk A/S will license the fully-human anti-Interleukin 21 monoclonal antibody developed by ZymoGenetics Inc. Celgene Corp. acquires Gloucester Pharmaceuticals for 340 million dollars.


Related Articles

  • ZymoGenetics Sold to Bristol-Myers.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p45 

    The article reports that ZymoGenetics Inc. will be sold to New York-based Bristol-Myers Squibb Co. for 9.75 dollar-per-share in 2010.

  • Nordisk buys Italian plant.  // Chemical Week;9/15/1993, Vol. 153 Issue 9, p4 

    Reports on Novo Nordisk's purchase of Bristol-Myers Squibb's penicillin fermentation plant at Anagni, Italy. Date of start of production; Company's discontinuation of basic production of penicillin at its plant in Kalundborg, Denmark.

  • The Industry.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p7 

    The article offers news briefs related to pharmaceutical industries in the U.S. Kevin Kruse was appointed as the new executive director of the Society of Pharmaceutical and Biotech Trainers (SPBT). Bristol-Myers Squibb Co. has agreed to take on the biopharma company ZymoGenetics Inc. which hopes...

  • BRISTOL-MYERS SQUIBB CO.  // MondayMorning;7/16/2012, Vol. 20 Issue 28, p1 

    The article reports on the plan of Bristol-Myers Squibb Co. to buy all of the outstanding shares of diabetes drug maker Amylin Pharmaceuticals Inc. in the U.S. Bristol-Myers said that it planned to buy Amylin for $5 billion in cash. Moreover, the company added that it would pay $31 for each...

  • ZymoGenetics Skyrockets 84% on $885M BMS Offer. Young, Donna // BioWorld Today;9/9/2010, Vol. 21 Issue 174, p1 

    The article reports on the 885 million U.S. dollars takeover offer by Bristol-Myers Squibb Co. (BMS) to ZymoGenetics Inc. The boards of directors of both firms have agreed to the deal and calling for an increase in shares by 84% or 4.46 U.S. dollars, to close at 9.76 U.S. dollars. It is believed...

  • the BRIEFCASE.  // Seattle Business;Nov2010, Vol. 21 Issue 11, p16 

    The article presents business news briefs concerning the U.S. state of Washington including the closure of Cruise West in September 2010, an agreement between pharmaceuticals Dendreon and GlaxoSmithKline on providing antigen, and the acquisition of ZymoGenetics by Bristol-Myers Squibb.

  • Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall. Dorey, Emma // Nature Biotechnology;Nov2010, Vol. 28 Issue 11, p1137 

    The article focuses on the 885 million U.S. dollar buyout of ZymoGenetics by Bristol-Myers Squibb (BMS). The full control of polyethylene glycol (PEGylated)-novel interferon of ZymoGenetics is believed to be the highlight of the deal for MS. On the other hand, BMS will develop its six-early...

  • News in brief.  // Nature Reviews Drug Discovery;Mar2010, Vol. 9 Issue 3, p181 

    The article offers news briefs from the pharmaceutical industry in the U.S. Food & Drug Administration (FDA) in the U.S. has approved Novo Nordisk A/S created drug peptide 1 (GLP1) analogue liraglutide. Pharmaceutical companies including Pfizer Inc. and GlaxoSmithKline have announced...

  • ENDOCRINE SYSTEM.  // MPR - Residents' Edition;Spring/Summer2010, Vol. 19 Issue 1, p80 

    The article offers information on several pharmaceutical products for types 1 and 2 diabetes. Apidra from Sanofi Aventis Ltd. is an insulin glulisine used in treating the two diabetes types. Avapro from Bristol-Myers Squibb Co. is used in treating type-2 diabetics with hypertension. Glucagen...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics